Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.

AIDS (London, England) - 24 Apr 2010

Maserati Renato, De Silvestri Annalisa, Uglietti Alessia, Colao Grazia, Di Biagio Antonio, Bruzzone Bianca, Di Pietro Massimo, Re Maria Carla, Tinelli Carmine, Zazzi Maurizio

Abstract excerpt

OBJECTIVE: To compare the emergence of drug-resistant HIV variants at failure of lamivudine (3TC)/tenofovir (TDF)-containing or emtricitabine (FTC)/TDF-containing HAART as a consequence of the different 3TC and FTC intracellular half-lives. DESIGN: Retrospective evaluation of 859 patients selecte...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Emtricitabine

Share to Lamivudine

Share to Organophosphonates

Share to Tenofovir

Share to Treatment Failure

Source

Identifiers

PMID: 20124969
DOI: 10.1097/QAD.0b013e328336e962

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20124969-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.PMID 20124969Read ↗

Different Evolution of Genotypic Resistance Profiles to Emtricitabine Versus Lamivudine in Tenofovir-Containing RegimensSemantic proximity Read ↗

Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.Semantic proximity Read ↗

Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.Semantic proximity Read ↗

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimensSemantic proximity Read ↗

Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.Semantic proximity Read ↗

Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.Semantic proximity Read ↗

Factors associated with virological failure in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence. ANRS-CO3-AquiVIH-NA cohort.Semantic proximity Read ↗

Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.Semantic proximity Read ↗

Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study.Semantic proximity Read ↗

Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.Semantic proximity Read ↗

Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.Semantic proximity Read ↗

Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.